Capricor

118 articles with Capricor

• 

  SoCal’s Capricor Places Voluntary Hold on DMD Drug Following Allergic Reaction

  12/26/2018

  Capricor Therapeutics has placed a voluntary hold on its Phase II clinical trial for a Duchene Muscular Dystrophy treatment on hold after a patient experienced a severe allergic reaction during dosing.

• Capricor Therapeutics to Present at 2018 Cell & Gene Meeting on the MesaCompany will Provide Presentation on Cell and Exosome Therapies and Poster on New Research

  10/3/2018

  Capricor Therapeutics, Inc. will provide a presentation at the 2018 Cell & Gene Meeting on the Mesa today on its cell therapy, CAP-1002, which is currently in clinical development for the treatment of Duchenne muscular dystrophy.

• Capricor Therapeutics to Present Second Quarter Financial Results and Corporate Update on August 9, 2018

  8/2/2018

  Capricor Therapeutics will report its second  quarter of 2018 financial results and corporate update shortly after the NASDAQ market close on Thursday, August 9. Management will then host a webcast and conference call at 4:30 p.m. ET on August 9.

• Capricor and USAISR Announce Collaboration to Investigate Exosome Platform to Treat Injured Troops

  7/17/2018

  Capricor Therapeutics announced it has entered into an agreement with the U.S. Army Institute of Surgical Research (USAISR) to study the potential for the company’s next-generation investigational therapeutic platform, designated CAP-2003

• Capricor to Give Update on HOPE-2 Clinical Trial for CAP-1002 at International Conference on Duchenne Muscular Dystrophy

  2/12/2018

  The three-day conference brings together scientists, physicians, companies, patients and their families to discuss the latest developments in Duchenne and Becker muscular dystrophy.

• Capricor Announces Licensing of Additional Patent Applications From Cedars-Sinai Medical Center for Cellular and Exosome-Based Technologies

  1/16/2018

  New patent applications pave way for capricor to develop potential new therapeutic platforms for duchenne muscular dystrophy and other disorders.

• Capricor Therapeutics Announces Issuance of Key U.S. Patent on Exosome Technology

  12/13/2017

  Capricor today announced that the U.S. Patent and Trademark Office has issued U.S. Patent 9,828,603, which includes composition of matter claims covering cardiosphere-derived cell exosomes.

• Capricor Therapeutics Announces FDA Clearance of IND Application for CAP-1002

  11/29/2017

  This randomized, double-blind, placebo-controlled clinical trial will be called the HOPE-2 Trial.

• Significant Improvements Reported in Duchenne Muscular Dystrophy Patients Treated With Capricor's Investigational Cell Therapy

  11/15/2017

  These findings were reported today by Ronald G. Victor, M.D. at a Late-Breaking Science session of the American Heart Association Scientific Sessions 2017.

• Capricor Therapeutics Reports Third Quarter 2017 Financial Results and Provides Update on Duchenne Muscular Dystrophy Development Program

  11/9/2017

  The company reported a net loss of approximately $2.7 million, or $0.12 per share, for the third quarter of 2017, compared to a net loss of approximately $5.3 million, or $0.29 per share, for the third quarter of 2016.

• Capricor Third Quarter 2017 Update Webcast and Conference Call Scheduled for Wednesday, November 8

  11/2/2017

  Capricor will report third quarter 2017 financial results shortly after the NASDAQ market close on Wednesday, November 8, 2017.

• Capricor Reports Intravenous Administration Of CAP-1002 Shown To Be Effective In Preclinical Models Of Duchenne Muscular Dystrophy

  10/6/2017

• Capricor Presents Positive Six-Month Results In Duchenne Muscular Dystrophy At World Muscle Society International Congress

  10/4/2017

• Capricor Advances Clinical Development Program In Duchenne Muscular Dystrophy With Naming Of Principal Investigator

  9/26/2017

• Capricor Reports Second Quarter 2017 Financial Results And Provides Corporate Update

  8/11/2017

• Capricor Second Quarter 2017 Update Webcast And Conference Call Scheduled For Thursday, August 10

  8/4/2017

• Capricor Announces Results Of FDA Meeting On Intravenous CAP-1002 For Duchenne Muscular Dystrophy

  7/27/2017

• Capricor Receives Rare Pediatric Disease Designation From FDA For CAP-1002 For Patients With Duchenne Muscular Dystrophy

  7/18/2017

• Capricor Falls as Johnson & Johnson Bails on Stem Cell Heart Med

  7/7/2017

• Capricor Announces Upcoming Events In Duchenne Muscular Dystrophy Program

  5/31/2017